PDF(Pubmed)
Abstract：
Our study aimed to determine the publication rates of podium presentations from the 2017 and 2018 Society of Gynecologic Oncology (SGO) Annual Meetings; and to examine rates and predictors of oral presentations that resulted in publication.
We reviewed podium presentations given at the 2017 and 2018 SGO Annual Meetings. Abstracts were evaluated for publication from January 1, 2017 to March 30, 2020 and January 1, 2018 to June 30, 2021, respectively, to allow for a 3 year period of publication.
In 2017 and 2018, 43 of 75 (57.3%) and 47 of 83 (56.6%) podium presentations were published within 3 years, respectively. No significant difference was found between the mean time to publication within 3 years (13.0 months vs 14.1 months for 2017 and 2018, respectively; p=0.96). Similarly, the mean difference of journal impact factors between both years did not reach significance (6.57 and 10.7 for 2017 and 2018, respectively; p=0.09). The median impact factor (IF) was 4.54 (range: 40.3) and 4.62 (range: 70.7) in 2017 and 2018, respectively. Of the presentations published, 53.4% (2017) and 38.3% (2018) appeared in the journal Gynecologic Oncology. Significant positive correlations for the likelihood of publication were determined among the following: funding status (r=0.93) including funding involving National Institutes for Health (r=0.91) or pharmaceutical (r=0.95), clinical trial study design (r=0.94), and pre-clinical research (r=0.95) (all p<0.005).
At the 2017 and 2018 SGO Annual Meetings 57% of podium presentations were published in a peer-reviewed journal within 3 years. Publication in peer-reviewed journals is crucial for timely distribution of clinical information to the medical community.
We reviewed podium presentations given at the 2017 and 2018 SGO Annual Meetings. Abstracts were evaluated for publication from January 1, 2017 to March 30, 2020 and January 1, 2018 to June 30, 2021, respectively, to allow for a 3 year period of publication.
In 2017 and 2018, 43 of 75 (57.3%) and 47 of 83 (56.6%) podium presentations were published within 3 years, respectively. No significant difference was found between the mean time to publication within 3 years (13.0 months vs 14.1 months for 2017 and 2018, respectively; p=0.96). Similarly, the mean difference of journal impact factors between both years did not reach significance (6.57 and 10.7 for 2017 and 2018, respectively; p=0.09). The median impact factor (IF) was 4.54 (range: 40.3) and 4.62 (range: 70.7) in 2017 and 2018, respectively. Of the presentations published, 53.4% (2017) and 38.3% (2018) appeared in the journal Gynecologic Oncology. Significant positive correlations for the likelihood of publication were determined among the following: funding status (r=0.93) including funding involving National Institutes for Health (r=0.91) or pharmaceutical (r=0.95), clinical trial study design (r=0.94), and pre-clinical research (r=0.95) (all p<0.005).
At the 2017 and 2018 SGO Annual Meetings 57% of podium presentations were published in a peer-reviewed journal within 3 years. Publication in peer-reviewed journals is crucial for timely distribution of clinical information to the medical community.
摘要：
目的：我们的研究旨在确定2017年和2018年妇科肿瘤学会（SGO）年会讲台演讲的发表率;并检查导致发表的口头报告的率和预测因素。
方法：我们回顾了在2017年和2018年SGO年会上的讲台演讲。摘要分别于2017年1月1日至2020年3月30日和2018年1月1日至2021年6月30日评估出版，允许三年的出版期。
结果：在2017年和2018年，在3年内发表了75个演讲中的43个（57.3％）和83个演讲中的47个（56.6％），分别。在3年内的平均出版时间之间没有发现显着差异（2017年和2018年分别为13.0个月和14.1个月；p=0.96）。同样，两年间期刊影响因子的平均差异未达到显著性(2017年和2018年分别为6.57和10.7;p=0.09).2017年和2018年的影响因子（IF）中位数分别为4.54（范围：40.3）和4.62（范围：70.7）。在发表的演讲中，53.4％（2017年）和38.3％（2018年）出现在《妇科肿瘤学》杂志上。在以下各项中确定了发表可能性的显着正相关：资金状况（r=0.93），包括涉及国立卫生研究院（r=0.91）或药物（r=0.95）的资金，临床试验研究设计（r=0.94），和临床前研究（r=0.95）（所有p<0.005）。
结论：在2017年和2018年的SGO年会上，57％的讲台演讲在3年内发表在同行评审的期刊上。在同行评审的期刊上发表对于及时向医学界分发临床信息至关重要。
方法：我们回顾了在2017年和2018年SGO年会上的讲台演讲。摘要分别于2017年1月1日至2020年3月30日和2018年1月1日至2021年6月30日评估出版，允许三年的出版期。
结果：在2017年和2018年，在3年内发表了75个演讲中的43个（57.3％）和83个演讲中的47个（56.6％），分别。在3年内的平均出版时间之间没有发现显着差异（2017年和2018年分别为13.0个月和14.1个月；p=0.96）。同样，两年间期刊影响因子的平均差异未达到显著性(2017年和2018年分别为6.57和10.7;p=0.09).2017年和2018年的影响因子（IF）中位数分别为4.54（范围：40.3）和4.62（范围：70.7）。在发表的演讲中，53.4％（2017年）和38.3％（2018年）出现在《妇科肿瘤学》杂志上。在以下各项中确定了发表可能性的显着正相关：资金状况（r=0.93），包括涉及国立卫生研究院（r=0.91）或药物（r=0.95）的资金，临床试验研究设计（r=0.94），和临床前研究（r=0.95）（所有p<0.005）。
结论：在2017年和2018年的SGO年会上，57％的讲台演讲在3年内发表在同行评审的期刊上。在同行评审的期刊上发表对于及时向医学界分发临床信息至关重要。
